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Orexin makes an important contribution to the regulation of cardiovascular function.
When injected centrally under anesthesia, orexin increases blood pressure, heart rate
and sympathetic nerve activity. This is consistent with the location of orexin neurons
in the hypothalamus and the distribution of orexin terminals in the central autonomic
network. Thus, the two orexin receptors, Ox1R and Ox2R, which have partly overlapping
distributions in the brain, are expressed in the sympathetic preganglionic neurons (SPN) of
the thoracic cord as well as in regions such as the pressor area of the rostral ventrolateral
medulla (RVLM). Both Ox1R and Ox2R appear to contribute to the cardiovascular effects of
orexin, although Ox1R is probably more important. Blockade of orexin receptors reduces
the cardiovascular response to certain stressors, especially psychogenic stressors such
as novelty, aggressive conspecifics and induced panic. Blockade of orexin receptors
also reduces basal blood pressure and heart rate in spontaneous hypertensive rats, a
model of essential hypertension. Thus, there is a link between psychogenic stress, orexin
and elevated blood pressure. The use of dual orexin receptor antagonists (DORAs) and
selective orexin receptor antagonists (SORAs) may be beneficial in the treatment of certain
forms of hypertension.
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INTRODUCTION
Orexin contributes to the central regulation of cardiovascular
function because it is a key player in the control of wakefulness
and arousal. Indeed, to stay awake and interacting with the envi-
ronment requires autonomic and cardiovascular adjustments not
only to support muscle activity but also to prepare for muscle
activity, as is the case for motivated behaviors and emotions. This
link with arousal and motivated behavior makes orexin a signif-
icant new player in the field of central cardiovascular control.
Most of our knowledge of central cardiovascular control is based
on brainstem-mediated short-term homeostatic regulation that
has been studied in the anesthetized preparation, while compar-
atively little is known about suprabulbar regulation in relation to
behavior and emotions. In other words, orexin reveals another
dimension of central cardiovascular control, one that could lead
to new therapeutic interventions in some forms of cardiovascu-
lar diseases, such as for example, stress related hypertension or
essential hypertension.
EARLY STUDIES
The cardiovascular effects of orexin were first demonstrated in
1999 by Samson et al. (1999) and Shirasaka et al. (1999). Both
studies showed that orexin A and orexin B (OxA, OxB, 1–5 nmol)
could evoke marked and sustained increases in blood pressure
when injected in the lateral ventricle of freely moving rats. Both
reported a stronger effect with OxA than OxB. Most importantly,
Shirasaka et al. showed (i) that this pressor effect was associ-
ated with an increase in heart rate and renal sympathetic nerve
activity and (ii) that the same effects could still be evoked under
anesthesia. The later two findings established without doubt that
the cardiovascular effect of orexin was due to a direct central
sympathoexcitatory action. This was confirmed shortly after in
a series of three papers by Dun and collaborators (Chen et al.,
2000; Dun et al., 2000; Antunes et al., 2001). They showed that the
same cardiovascular effects were still evoked (i) by intracisternal
and intrathecal (T2–T3) injections of OxA and OxB and (ii) by
microinjections of OxA in the vasopressor area of the rostral ven-
trolateral medulla [RVLM, (Chen et al., 2000; Dun et al., 2000)].
They also demonstrated that OxA and OxB directly depolarize
vasopressor neurons of the RVLM and sympathetic preganglionic
neurons (SPN) in the thoracic cord (Dun et al., 2000; Antunes
et al., 2001).
Pharmacological blockade studies were not possible at the time
due to lack of receptor antagonists. However, a seminal study by
Kayaba et al. (2003) showed that orexin knock out mice had (i)
a reduced basal blood pressure and (ii) a reduced cardiovascu-
lar response to a psychosocial stressor (resident-intruder test),
but not to a noxious stimulus (tail pinch). This study suggested
an important role of orexin in the cardiovascular response to
motivated behavior.
ANATOMY OF THE OREXIN SYSTEM IN RELATION TO THE
CENTRAL AUTONOMIC NETWORK
OREXIN NEURONS AND THEIR CONNECTIONS
The neurons that make orexin are found in the dorsal part of
the tuberal hypothalamus, nowhere else in the brain. The group
is centered on the perifornical area (PeF) and extends medially
into the dorsomedial hypothalamic nucleus and laterally into
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the lateral hypothalamic area (Peyron et al., 1998; Nambu et al.,
1999). Interestingly, this region corresponds relatively well to
the classic hypothalamic defense area, a region identified more
than 50 years ago and from which powerful behavioral and
cardiovascular responses can be evoked (Hilton, 1982; Carrive,
2011).
Specific inputs to orexin neurons, identified with a geneti-
cally encoded retrograde tracer (Sakurai et al., 2005) or from
appositions of anterogradely labeled terminals (Yoshida et al.,
2006), originate mostly from forebrain areas, either limbic [lateral
septum, bed nucleus of the stria terminalis (BNST), amygdala,
infralimbic cortex] or hypothalamic (preoptic area, posterior
hypothalamus). These regions are also well known for their role
in emotions and autonomic control (Saper, 2004).
On the output side, orexin terminals can be seen not only in
the limbic structures described above where they make recip-
rocal connections, but also in all the autonomic centers of the
hypothalamus and brainstem, including the periaqueductal gray
(PAG), parabrachial nucleus, nucleus of the solitary tract (Sol),
the premotor sympathetic centers of the paraventricular nucleus
of the hypothalamus (Pa), rostral ventrolateral and ventrome-
dial medulla (RVLM, RVMM) and medullary raphe (Figure 1)
(Peyron et al., 1998; Nambu et al., 1999; Baldo et al., 2003; Ciriello
and De Oliveira, 2003; Ciriello et al., 2003; Zheng et al., 2005;
Shahid et al., 2012). Orexin neurons are also themselves premo-
tor sympathetic neurons since they directly innervate SPN (Van
Den Pol, 1999; Date et al., 2000; Llewellyn-Smith et al., 2003).
Projections are also found in the dorsal motor nucleus of the
vagus although the projection may be weak (Peyron et al., 1998;
De Oliveira et al., 2003). Thus, orexin neurons can act at all lev-
els of the central autonomic network, from limbic structures to
premotor autonomic centers to the SPNs themselves.
OREXIN RECEPTORS AND THEIR DISTRIBUTION
There are two orexin receptors, Ox1R and Ox2R (Gotter et al.,
2012). OxA can act on both Ox1R and Ox2R while OxB acts
primarily on Ox2R. The two receptors have a differential, partly
overlapping distribution in the brain, including within the cen-
tral autonomic network (Figure 1). However, it is not clear how
the two receptors relate to the cardiovascular functions of orexin.
Three main in situ hybridization studies have compared the
distribution of the two receptors in the brain and hypothala-
mus (Trivedi et al., 1998; Lu et al., 2000; Marcus et al., 2001).
They show that the BNST expresses both receptors while the
amygdala primarily expresses Ox1R and the septum primarily
Ox2R. In the hypothalamus, most areas express both receptors,
FIGURE 1 | Schematic overview of the orexinergic pathways involved in
the descending control of sympathetic output to cardiovascular effectors.
The contribution of Ox1R and Ox2R at each level is represented by the relative
size of the Ox1R and Ox2R labels. This is a tentative representation only,
reflecting the current stage of our knowledge. Abbreviations: Pa,
paraventricular nucleus of the hypothalamus; RVLM, rostral ventrolateral
medulla; RVMM, rostral ventromedial medulla (plus medullary raphe); Sol,
solitary nucleus; SPN, sympathetic preganglionic neurons.
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except Pa, which appears to exclusively express Ox2R. In the
brainstem, most of the autonomic areas described above also
express both receptors, except for the A5 catecholaminergic cell
group, which like the A6 group of the locus coeruleus exclu-
sively expresses Ox1R. Single cell RT-PCR in SPNs show that
Ox1R is easier to detect than Ox2R (Van Den Top et al.,
2003).
Immunohistochemical studies of Ox1R and Ox2R distribu-
tion (Hervieu et al., 2001; Cluderay et al., 2002) have confirmed
the overall distribution of the two receptors, but they also show
more overlap than suggested by the in situ hybridization stud-
ies. For instance, the amygdala also contains Ox2R and the
septum Ox1R. More importantly, Pa also contains a significant
amount of Ox1R in both its magno- and parvocellular areas,
which colocalizes with vasopressin/oxytocin and CRF, respec-
tively (Hervieu et al., 2001; Bäckberg et al., 2002). Interestingly,
orexin neurons themselves have both receptors as autoreceptors
(Bäckberg et al., 2002; Yamanaka et al., 2010). Other reports con-
firm dense Ox1R labeling in the RVMM area (Ciriello and De
Oliveira, 2003; Ciriello et al., 2003) and both Ox1R and Ox2R
in C1 neurons of the RVLM (Shahid et al., 2012). The pres-
ence of Ox1R and Ox2R in SPNs remains to be verified by
immunohistochemistry.
OREXIN RECEPTORS MEDIATING THE CARDIOVASCULAR
EFFECTS OF CENTRALLY INJECTED EXOGENOUS OREXIN
Given the partly overlapping distribution of Ox1R and Ox2R in
central autonomic structures, it is not clear if one receptor or the
other or both mediate(s) the cardiovascular effect of orexin. This
question can be answered by challenging the effect of exogenous
OxA (which acts on both receptors) with selective orexin receptor
antagonists (SORA) or by using selective agonists. The two Ox1R
SORA are SB334867, the most popular, and SB408124 (Scammell
and Winrow, 2011; Gotter et al., 2012; Morairty et al., 2012). So
far the only Ox2R SORA to have been used in this field of research
is TCS-OX229 (Hirose et al., 2003), although a number of studies
have also used the selective Ox2R agonist, [Ala11,D-Leu15]-OxB
(Asahi et al., 2003).
OREXIN MICROINJECTED IN THE VENTRICLES OR SUBARACHNOID
SPACE
Hirota et al. (2003) were the first to demonstrate that prior
blockade of Ox1R with intracerebroventricular (icv) injections
of the Ox1R antagonist SB334867 (50 nmol) could almost com-
pletely block the cardiovascular response of icv OxA (50 nmol).
This was confirmed in the awake rat using smaller doses of icv
OxA (3 nmol) and another Ox1R antagonist, SB408124 (3 nmol)
(Samson et al., 2007). Similarly, spinal intrathecal injections of
SB334867 (200 nmol) almost completely blocked the pressor,
tachycardic, and sympathetic nerve response to intrathecal OxA
(50 nmol) (Shahid et al., 2011). However, Huang et al. (2010)
showed that the Ox2R antagonist TCS-OX229 (3 and 10 nmol)
was more potent than SB334867 (3 and 10 nmol) in reducing the
pressor and tachycardic effect of OxA (3 nmol) when injected in
the cisterna magna. These studies suggest that Ox1R is important,
but Ox2R, which has not been challenged asmuch as Ox1R,might
be equally as important.
OREXIN MICROINJECTED WITHIN REGIONS OF THE CENTRAL
AUTONOMIC NETWORK
SPN
Injection of OxA and OxB on identified SPN evokes strong depo-
larization due to a direct postsynaptic action (Antunes et al., 2001;
Van Den Top et al., 2003). The response was as strong with OxA as
with OxB, and OxA’s effect was only reduced by 60% after block-
ade with SB334867 (Van Den Top et al., 2003). It led these authors
to suggest that both receptors might be involved.
RVLM
A similar study on neonate RVLMpressor neurons byHuang et al.
(2010) revealed equipotent depolarizing effect of OxA, OxB and
the specific OxB agonist [Ala11,D-Leu15]-OxB. These authors
further showed that TCS-OX229 was more potent than SB334867
in reducing the effect of OxA (Huang et al., 2010). Similar obser-
vations were reported by Shahid et al. (2012) who showed that
OxA and [Ala11,D-Leu15]-OxB had equipotent cardiovascular
effects when injected in the RVLM and that SB334867 reduced
OxA’s effect by half.
Sol
Injections of low doses (2.5–5 pmol) of OxA and OxB in the
nucleus of the solitary nucleus evokes equipotent bradycradic and
depressor responses (De Oliveira et al., 2003; Shih and Chuang,
2007; Ciriello et al., 2013), however at higher dose (>40 pmol)
both evoke tachycardic and pressor responses, with OxA more
potent than OxB. The effects appear to bemediated by both Ox1R
and Ox2R (Shih and Chuang, 2007).
Others
When injected in the medullary raphe area, OxA produces tachy-
cardic effects at low dose (2.5 pmol) and pressor and tachycardic
effects at high dose (30 pmol) (Luong and Carrive, 2012). In con-
trast, OxA evokes bradycardic effects when injected in the external
part of the Ambiguus nucleus, presumably by activating vagal pre-
ganglionic neurons (Ciriello and De Oliveira, 2003). However, it
is not known what receptor mediates these effects, although these
two areas have been shown to contain Ox1R.
To summarize, the cardiovascular effect of exogenous orexin
can in large part be explained by an action through Ox1R at
almost all levels (Figure 1). However, in the RVLM, one of
the most important vasopressor center in the brain, an action
through Ox2R appears as important, ifnot more. Ox2R may also
contribute at the level of SPNs themselves.
OREXIN RECEPTORS MEDIATING THE CARDIOVASCULAR
RESPONSES OF CENTRALLY RELEASED, ENDOGENOUS
OREXIN
Orexin microinjections may reveal important properties of
orexin’s loci and mode of action, but the main question is
how endogenous orexin acts in the behaving animal, where and
through which receptors. Coordinated release of orexin at mul-
tiple levels of the neuraxis in synchrony with activation of other
non-orexinergic system would have far more subtle effects than
those of a ventricular or intracerebral injection. The approach
therefore consists in first identifying behavioral conditions or
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pathological states associated with orexin release and then chal-
lenging these responses or states with systemic injections of dual
and selective orexin receptor antagonists (DORA and SORA).
Almorexant (Brisbare-Roch et al., 2007; Morairty et al., 2012) is
the main DORA that has been used so far in relation to central
autonomic control. The SORAs are the same as those described
above.
CENTRALLY EVOKED RESPONSES
Disinhibition of the PeF is one way of inducing an orexin-
mediated response. Remarkably, although orexin neurons (i)
contain other peptides and use glutamate as their main neu-
rotransmitter and (ii) only represent a fraction of the output
neurons of the perifornical area, still, 50% of the tachycardic
and pressor response obtained by bicuculline injection in the
perifornical hypothalamus is blocked by systemic administration
of Almorexant (15mg/kg, iv) (Iigaya et al., 2012). This indi-
cates that the peptide plays an important role in the output of
this area. As suggested by the cardiovascular effects of OxA in
the medulla and spinal cord described above, it is likely that
Almorexant will exert its effect via an action on the targets of
orexin neurons, however, part of its action maybe in the peri-
fornical area itself since Almorexant microinjections in the PeF
can reduce the tachycardic and pressor responses to perifornical
disinhibition (Stettner and Kubin, 2013).
Similar results have been reported with Ox1R SORAs. In the
rabbit, SB334867 and SB408124 (7mg/kg, iv) markedly reduced
the pressor response evoked by electrical stimulation of the dorsal
hypothalamus and PAG (Nisimaru et al., 2013). In conscious rat
SB334867 (10mg/kg, iv) also reduced by about 40–50% the tachy-
cardic, pressor and hyperthermic response to muscimol injection
in the medial preoptic area, an area that exerts a tonic inhibition
of the dorsal hypothalamic area (Rusyniak et al., 2011).
PSYCHOLOGICAL STRESSORS AND INDUCED PANIC
A number of psychological stressors have been challenged with
Almorexant or Ox1R SORAs. Novelty, conditioned fear to con-
text, restraint and cold exposure, all evoke tachycardic and pressor
responses, however, Almorexant (300mg/kg, io) affected only
novelty and contextual fear (Furlong et al., 2009). The pres-
sor responses to novelty and conditioned fear, the tachycardic
response to novelty and the cardiac sympathetic response to con-
ditioned fear were reduced by 45% ormore, but restraint and cold
exposure were not significantly affected by Almorexant (Furlong
et al., 2009). This led the authors to suggest that the stress
responses to which orexin contribute might be more psychologi-
cal than physical, reminiscent of the observation by Kayaba et al.
(2003), that the cardiovascular response to pinch was not affected
in knock out orexin mice, whereas that to social stress was.
The other studies have used Ox1R SORAs, mainly SB334867.
A major study by Johnson et al. (2009) showed that both the
pressor and tachycardic responses evoked by sodium lactate in
panic prone rats were markedly reduced by systemic SB334867
(30mg/kg, ip). A similar effect was observed with SB408124
(30mg/kg, ip also). The same high dose of SB334867 also reduced
the pressor (but not bradycardic) response to hypercapnia (20%
CO2, a suffocation signal) as well as the tachycardic (but not
pressor) response to the anxiogenic partial inverse benzodi-
azepine agonist FG7142 (Johnson et al., 2012a,b). SB334867
(10mg/kg, iv) also reduces the pressor but not tachycardic
response to a moderate dose of metamphetamine (Rusyniak et al.,
2012). Finally, a recent study with a new selective Ox1R antagonist
(ACT335827, 100–300mg/kg, io) reported a significant reduc-
tion of the tachycardic (but not pressor) response to social stress
(Steiner et al., 2013).
This indicates that orexin contributes to the cardiovascular
components of some forms of stress as initially shown in orexin
knock-out mice by Kayaba et al. (2003). The Ox1R appears to
play an important part in this, however the dose of Ox1R antag-
onists used in these studies is very high. They could be acting on
Ox2R as well. Unfortunately, the contribution of Ox2R is not yet
known as no study has tried to challenge these responses with
Ox2R antagonists.
CHRONIC STRESS-INDUCED AND SPONTANEOUS HYPERTENSION
Recent work has revealed a potentially important role of orexin in
stress-induced or spontaneous forms of hypertension.
Xiao et al. (2012) used electric shocks over a period of 14
days to produce a stress-induced hypertensive state (+30mmHg).
Remarkably, this treatment doubled the number of orexin
neurons and almost doubled the amount of Ox1R in the RVLM
(Ox2R was not investigated). Consistent with this effect, unilat-
eral microinjections of OxA in RVLM produced greater pressor
and tachycardic responses in these animals. Conversely, RVLM
injections of the Ox1R SORA SB408124 reduced systolic pres-
sure and heart rate in those hypertensive animals but not in the
normotensive non-stressed controls. Interestingly, Ox2R was also
involved since the Ox2R SORA TCS-OX229 reduced systolic pres-
sure in these hypertensive animals. This study shows that chronic
stress can upregulate the orexin system and that both receptors,
with possibly a dominance of the Ox1R, mediate the resulting
hypertension. Most remarkable is the increase in orexin neurons
as a result of chronic stress.
Finally, two recent studies suggest that essential hypertension
in the Spontaneously hypertensive rat (SHR) may in part be due
to an overactive orexin system. Thus, Li et al. (2013) have shown
that oral administration of Almorexant in the conscious SHR
reduces mean arterial blood pressure (∼30mmHg), heart rate
and plasma noradrenaline during both wakefulness and NREM
sleep, but has no significant effect in normotensive WKY rats.
Lee et al. (2013) further showed in the anaesthetized SHR that
icv TCS-OX229 (10 and 30 nmol) but not SB334867 (100 nmol)
reduced MAP and HR. Surprisingly, there was a reduction of
Ox2R density in the RVLM, but no change in PVN, DMH/PeF,
and caudal NTS. Ox1R was also the same as in WKY in all
four regions. Finally, bilateral injections of TCS-OX229 in the
RVLMmarkedly lowered MAP (∼30mmHg), suggesting that the
cause of the hypertensive phenotype in these animals could be an
over-activation of Ox2R.
BASAL BLOOD PRESSURE AND HEART RATE IN OREXIN
DEFICIENT HUMANS AND MICE
If orexin upregulation leads to hypertension, then one
would expect orexin downregulation or deficiency to lead
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to hypotension. Indeed, a reduced baseline blood pressure during
wakefulness has been reported in orexin knock-out and orexin
neuron-ablated mice (orexin-ataxin3 transgene) (Kayaba et al.,
2003; Lo Martire et al., 2012). However, other studies have
found no difference between these mice and wild type controls
(Bastianini et al., 2011; Silvani et al., 2013). Interestingly, in
human, patients with narcolepsy with cataplexy, which have
reduced levels of orexin and orexin neurons, also have normal
basal blood pressure when awake (Grimaldi et al., 2010, 2012;
Dauvilliers et al., 2012). In contrast, and somewhat unexpectedly,
baseline blood pressure during sleep tends to be higher than
in controls. Thus, in both patients and transgenic mice, the
circadian variation in blood pressure is consistently reduced. The
dip in blood pressure that is normally seen between wakefulness
and sleep is reduced, as is the rise in blood pressure when waking
up from sleep (Bastianini et al., 2011; Dauvilliers et al., 2012;
Grimaldi et al., 2012; Lo Martire et al., 2012; Silvani et al., 2013).
In terms of heart rate, the same studies in mice report either
no change (Kayaba et al., 2003; Lo Martire et al., 2012) or
an increase (Bastianini et al., 2011; Silvani et al., 2013) during
wakefulness, whereas in patients both increases (Grimaldi et al.,
2010, 2012; Sorensen et al., 2013) and decreases have been
reported (Dauvilliers et al., 2012). During sleep, heart rate may be
higher (Bastianini et al., 2011) or the same (Bastianini et al., 2011;
Lo Martire et al., 2012; Silvani et al., 2013) in transgenic mice,
and higher (Grimaldi et al., 2012) or the same (Dauvilliers et al.,
2012) in patients. Nevertheless, as observed with blood pressure,
the rise in heart rate at the transition between sleep and arousal is
reduced in both transgenic mice and narcoleptic patients (Silvani
et al., 2013; Sorensen et al., 2013).
To summarize, a chronic lack of orexin does not necessar-
ily lead to a lower blood pressure and heart rate, but it will
result in a blunted circadian variation of these parameters. There
may be a simple explanation to this. As suggested by Grimaldi
et al. (2012), the altered sleep/wake regulation could have a con-
founding effect opposing the direct sympatholytic effect of orexin
deficiency. Simply put, trying not to fall asleep during the active
period or conversely, being regularly awaken during the inactive
period, will both increase sympathetic activity. Nevertheless, a
more relevant observation with respect to narcoleptic patients is
their reduced autonomic response to emotional stimuli, especially
aversive ones (Tucci et al., 2003). In contrast, their cardiovascu-
lar response to basic homeostatic challenges such as head-up tilt,
Valsalva maneuver and cold pressor test are unaffected (Grimaldi
et al., 2010), which is consistent with orexin’s primary role in
motivated behavior.
CONCLUSION
The orexinergic system plays an important role in central car-
diovascular control. It is excitatory and contributes to the sym-
pathetic response associated with motivated behavior, including
some forms of stress. However, the mode of action of orexin is
far from clear. Orexin terminals and orexin receptors are found
in all the regions known to regulate cardiovascular function from
sympathetic motor to premotor autonomic to limbic levels. So
far anatomical and pharmacological evidences point toward a pri-
mary role for Ox1R, however this view is biased by the fact that
most studies have used Ox1R SORAs (i.e., SB334867). Ox2R is
also found in most central cardiovascular centers and when chal-
lenged is often found to be as important as Ox1R. Thus, it is not
clear how the two receptors interact and if their effects are addi-
tive or synergistic. Nevertheless, blockade of orexin receptors can
reduce the hypertension that is evoked by some acute psycholog-
ical stressors, induced by chronic stress or simply spontaneous
as in the case of adult SHR, a model of essential hyperten-
sion. Clearly there is an interesting link between psychogenic
stress, orexin, and elevated blood pressure. Further research in
SORAs and DORAs may well lead to the development of new
anti-hypertensive drugs.
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